Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

The Trump plan won't be limited to Medicare prescriptions and will also target medications covered by Medicaid and private ...

Key Takeaways Zepbound helped patients lose 50 pounds, compared to 33 pounds with WegovyThe study showed Zepbound users lost ...

Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England ...

Eventually, it was proven that Mounjaro is more affective than Wegovy in terms of weight loss, with 32 per cent of ...

In secondary endpoints, 64.6% of participants using Zepbound saw 15% weight loss compared with 40.1% on Wegovy. And Zepbound participants saw their waists reduced by an average 7.2 in (18.4 cm), ...

A doctor has issued a warning about a less documented side effect of Ozempic that can apparently have a long-term health ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.